Eli Lilly and Company (NYSE:LLY) finished Thursday with a subtraction of -$4.89 to close at $521.34, a downside of -0.93 percent. An average of 5,779,220 shares of common stock have been traded in the last five days. There was a gain of $72.18 in the past week, and it reached a new high 44 times over the past 12 months. The last 20 days have seen an average of 3,067,150 shares traded, while the 50-day average volume stands at 2,859,604.
LLY stock has increased by 18.33% in the last month. The company shares reached their 1-month lowest point of $434.34 on 07/13/23. With the stock rallying to its 52-week high on 08/08/23, shares of the company touched a low of $296.32 and a high of $538.00 in 52 weeks. It has reached a new high 27 times so far this year and achieved 42.50% or $155.50 in price. In spite of this, the price is down -3.10% from the 52-week high.
Insider Transactions
LLY stock investors should be aware that Eli Lilly and Company (LLY) stock had its last reported insider trading activity 2 days ago on Aug 09. In this transaction, the insider spent $65,554,314. 10% Owner, LILLY ENDOWMENT INC, disposed of 204,409 shares at a price of $523.74 on Aug 08. The insider now owns more than $107,056,405 worth of shares. Prior to that, 10% Owner LILLY ENDOWMENT INC went on to Sale 591 shares at $466.62 each on Jul 21. An amount of $275,773 was transacted.
Valuation Metrics
Eli Lilly and Company (LLY) has a trailing price-to-earnings (P/E) ratio of 82.77. The stock’s beta is 0.32. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 17.86, the price-to-book (PB) ratio at 41.98, and the price-to-cash flow ratio at 4190.96.
Financial Health
The quick ratio of Eli Lilly and Company for the recent quarter was 1.00, and the current ratio was 1.30, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 1.69 and a total debt to equity ratio of 1.69 for the recent quarter. Eli Lilly and Company’s EBITDA margin is 34.35%, while its operating margin for the same period stands at 22.50%. Its gross profit as reported stood at $21.91 billion compared to revenue of $28.54 billion.
Earnings Surprise
For the recent quarter, Eli Lilly and Company had $134.6 million in cash and short-term investments compared to $18.16 billion in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $1.76 billion in the quarter, while revenues of $1.34 billion were grew 45.98%. At the end of the recent quarter, Eli Lilly and Company’s stock balance sheet showed total liabilities of 43.66 billion. Shareholders own equity worth $949.29 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Eli Lilly and Company (LLY) price momentum. RSI 9-day as of the close on 10 August was 81.25%, suggesting the stock is Overbought, with historical volatility in this time frame at 69.79%.
As of today, LLY’s price is $494.55 +16.07% or $72.18 from its 5-day moving average. LLY is currently trading +19.93% higher than its 20-day SMA and +58.38% higher than its 100-day SMA. However, the stock’s current price level is +22.03% above the SMA50 and +52.99% above the SMA200.
The stochastic %K and %D were 83.66% and 66.21%, respectively, and the average true range (ATR) was 15.20. With the 14-day stochastic at 81.78% and the average true range at 13.25, the RSI (14) stands at 76.51%. The stock has reached 47.05 on the 9-day MACD Oscillator while the 14-day reading was at 53.92.
Analyst Ratings
Jefferies upgraded Eli Lilly and Company (NYSE: LLY) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a Hold. The consensus rating for Eli Lilly and Company (LLY) among analysts is Overweight. According to current brokerage recommendations, 1 brokerage firm advise that investors sell LLY, while 6 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 20 others rate it as a “buy”.
What is LLY’s price target for the next 12 months?
Analysts predict a range of price targets between $312.00 and $633.00, with a median target of $570.00. Taking a look at these predictions, the average price target given by analysts for Eli Lilly and Company (LLY) stock is $544.99.
